Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Abstract

Vyshak Alva Venur,1 Monika Joshi,2 Kenneth G Nepple,3 Yousef Zakharia1 1Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA, 3Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA Abstract: Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC. Keywords: renal cell carcinoma, kidney cancer, PD-1, nivolumab, immunotherapy

Keywords

• Renal cell carcinoma
• kidney cancer
• PD-1
• nivolumab
• immunotherapy